EMA Awards Orphan Drug Designation to Loxo Oncology for LOXO-101

The European Medicines Agency has blessed Loxo Oncology with orphan drug designation for LOXO-101, designed for the treatment of patients with soft tissue sarcoma.

LOXO-101 is being developed to treat patients with cancers containing abnormalities involving the tropomyosin receptor kinases.